Figure 2F presents the expression profiles of a representative glycopeptide—TANDTSTEAYNLLLR-N2H7F0S0G0@LAMC1—across NAT, tumor, and early-stage tumor samples, showing distinct upregulation at the glycoform level. The differential expression analysis of all LAMC1 glycopeptides (Fig. 2G) revealed substantial remodeling of glycosylation in tumors compared with NAT samples, encompassing both upregulated and downregulated glycoforms. This evidence concerns the gene BRD2 and neoplasm.